Core Insights - Sangoma Technologies Corporation reported solid first quarter results for Fiscal 2026, demonstrating the strength of its recurring revenue model and reaffirming its guidance for the fiscal year [2][4]. Financial Performance - Total revenue for the first quarter was $50.8 million, with a sequential growth expected in Q2. Excluding $7.6 million from VoIP Supply, LLC, revenue decreased by 3% year-over-year on a like-for-like basis [5]. - Average revenue per customer increased by 19% year-over-year, and bookings rose by 6%, supporting the growth outlook for the remainder of the year [5]. - Gross profit was $36.8 million, representing 72% of total revenue, an increase from 67% in the previous quarter, driven by a shift towards higher-margin recurring services [5]. - Operating expenses decreased by 9% year-over-year to $38.5 million, reflecting efficiency gains from transformation activities [5]. - The company reported a net loss of $2.3 million, compared to a net loss of $1.9 million in the same quarter last year [5]. - Adjusted EBITDA was $8.3 million, representing 16% of total revenue, consistent with historical seasonal patterns [5]. Guidance and Strategic Direction - Sangoma reaffirmed its guidance for Fiscal 2026, expecting total revenue in the range of $200 - $210 million, compared to $209 million in Fiscal 2025, excluding the contribution from VoIP Supply [4]. - The company is focused on expanding its software and services portfolio and deepening relationships with its global customer and partner base [2]. Shareholder Value and Capital Management - Free cash flow for the first quarter was $3.2 million, with net cash provided by operating activities at $4.9 million, representing 60% of Adjusted EBITDA [5]. - The company has repurchased over 700,000 shares under its Normal Course Issuer Bid, including 195,949 shares repurchased after the end of the first quarter [5].

Kornit Digital (NASDAQ: KRNT) Third Quarter 2025 Earnings Conference Call Supporting Slides November 5, 2025 Kornit Digital. All Rights Reserved. Kornit Digital. All Rights Reserved. On Today's Call Ronen Samuel CEO Lauri Hanover CFO Jared Maymon Investor Relations This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. securities laws. Forward-looking statements are characterized by the use of forward-looking terminol ...

Core Insights - Hims & Hers Health, Inc. (HIMS) operates a subscription-based revenue model that provides predictable cash flows through ongoing treatments and services [1][3] - The company is expanding its offerings into new categories such as weight loss, dermatology, mental health, and sexual health, which are designed to deepen customer engagement and broaden the subscriber base [2][7] - Hims & Hers emphasizes long-term customer relationships, prioritizing lifetime value and predictable revenues, which enhances customer loyalty and trust [3] Revenue Model - Hims & Hers generates revenue primarily through subscriptions that cover prescription medications, wellness products, and provider consultations [1][7] - The subscription plans offer flexible delivery schedules ranging from 30 to 360 days, allowing customers to tailor their experience [1] - The integrated technology platform streamlines the customer journey, enhancing operational efficiency and gross margins [1][3] Growth Strategy - The company’s expansion strategy is supported by the addition of new product categories that require recurring treatments, thereby attracting new customers and encouraging cross-selling [2][3] - Recent product launches, including exclusive testosterone offerings, aim to deepen engagement with existing subscribers [2][7] Financial Performance - Hims & Hers shares have increased by 139.4% year-to-date, significantly outperforming the industry growth of 38.9% [6] - The Zacks Consensus Estimate predicts a 122.2% improvement in earnings per share for 2025 compared to 2024 [8][11] - Hims & Hers has a forward 12-month price-to-sales ratio of 4.9X, which is lower than the industry average of 6.1X but higher than its three-year median of 2.5X [10]

Financial Data and Key Metrics Changes - Total net revenues for Q4 fiscal 2025 increased by 11.9% to $18.4 million, compared to $16.4 million in the prior year period [13] - Gross profit for Q4 was $10.3 million, representing a 56% gross margin, up from 52% in the prior year quarter [14] - Total net revenues for fiscal 2025 were $66.1 million, an increase from $61.4 million in fiscal 2024 [16] - Non-GAAP EBITDA for Q4 was $4.7 million, or $0.40 per diluted share, nearly quadrupling the prior year's Q4 figure of $1.2 million, or $0.11 per diluted share [15] Business Line Data and Key Metrics Changes - Subscription and support revenues for Q4 grew by 9.9% to $8.2 million, compared to $7.5 million in the same period last year [14] - Services revenues rose to $9.7 million, up from $8.4 million in the prior year period, reflecting strong project delivery [14] - Total subscription and support revenues for fiscal 2025 were $32.9 million, compared to $28 million in the previous year [16] Market Data and Key Metrics Changes - The company secured a $16 million five-year contract with a major U.S. automaker to transform its dealership operations [10] - A major Chinese automotive finance company upgraded to Transcend Finance as part of a multimillion-dollar deal involving the migration of over 3 million contracts [10] - The company made its official entry into the Middle East with a deal signed with Sinbad Management, SPC in Oman [10] Company Strategy and Development Direction - The company is focused on delivering long-term value through its unified AI-powered Transcend platform and expanding its presence in key global markets [5] - The strategy of migrating existing customers from a licensed revenue model to a recurring revenue model continues to accelerate [6] - Continued investment in AI and automation capabilities is aimed at optimizing operational efficiency and maintaining a disciplined cost structure [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth momentum, citing strong performance across all three regions [20] - The company plans to update guidance in the second quarter for better clarity on fiscal 2026 expectations [27] - Management believes the fundamentals of the business remain strong and is optimistic about opportunities ahead [31] Other Important Information - The company launched Transcend AI Labs, a dedicated innovation hub focused on AI-first enhancements and strategic consulting [9] - The leadership team was strengthened with key senior-level appointments, including Richard Howard and Ian Smith [11][12] Q&A Session Summary Question: Is the recent growth an anomaly or the start of a new trend? - Management believes there is enough momentum across all regions to support continued growth [20] Question: What is the payment frequency for subscription revenues? - Payments vary by contract, with some being annual, quarterly, or monthly [22] Question: What is the sales cycle for new contracts? - The sales cycle has lengthened, but significant work is done before contracts are signed to ensure timely implementation [23] Question: Will the company provide guidance for the next year? - Management prefers to update guidance in the second quarter for better clarity [27]

Core Insights - Cardiac Biotech Solutions, Inc. has received an initial purchase order from Noventis Medical for 2,500 MyCardia AT Cardiac Event Monitoring devices, valued at $375,000 USD [1][2] - The order includes immediate shipment of 1,000 devices, with the remaining 1,500 units to be delivered within 90 days [2] - The CEO of CBSC highlighted that this purchase order indicates strong market demand and initiates a sustainable revenue model through device sales and recurring software-driven rental fees [3] - CBSC has established a monthly rental program for ongoing revenue generation, which includes device usage, AWS Cloud-based monitoring software, and patient-facing applications [3][4] - Revenue from the rental program is shared, with CBSC receiving one-third of the monthly fee [4] - The MyCardia AT platform is advancing in global commercialization, with regulatory clearance in the U.S. and submissions in Canada and China [5] - Noventis Medical is a leading distributor of advanced medical technologies in Central America, focusing on innovative healthcare solutions [6] - CBSC provides non-invasive cardiac monitoring products and services, enhancing patient compliance and providing accurate information for physicians [7]

Core Insights - Plurilock Security Inc. has been named a Certified Services Partner for Forcepoint, enhancing its position in the cybersecurity market [1][5] - The partnership allows Plurilock to offer integrated services to Forcepoint customers, including implementation, policy tuning, hosting, and fully managed services [2][4] - This collaboration aims to provide operational value and support for organizations, particularly those with limited internal resources, by optimizing existing Forcepoint deployments [3][4] Company Developments - The partnership with Forcepoint is a continuation of Plurilock's earlier designation as an Authorized Managed Security Service Provider (MSSP) [5] - Plurilock's Critical Services will be integrated into its Data Protection as a Service (DPaaS) platform, providing centralized support across various environments [4][8] - The collaboration is already generating joint sales engagements and new leads in both enterprise and public sector accounts [3][7] Industry Context - The partnership reflects a growing trend in the cybersecurity industry towards AI-powered, unified data security solutions that adapt to risk and simplify protection across environments [4] - Plurilock's services are designed to reduce risk, ensure compliance, and enhance long-term system effectiveness for clients [4][5] - The collaboration positions Plurilock as a trusted advisor and managed cybersecurity provider in complex enterprise and regulated markets [5][6]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $270 million, an increase of $24 million from Q1 2024, but a decrease of $37 million from Q4 2024 [8][17] - Product revenues were $145 million, up $12 million year-over-year but down $37 million sequentially [9][18] - Service revenues were $125 million, an increase of $12 million from Q1 2024 and flat compared to Q4 2024 [9][18] - Non-GAAP gross margin for Q1 2025 was 42.1%, a decrease of 530 basis points from the prior quarter [9][19] - GAAP earnings per share for Q1 2025 was a loss of $0.15, compared to a loss of $0.34 in Q1 2024 [10][20] - Non-GAAP earnings per share for Q1 2025 was $0.26, compared to $0.03 in the same period last year [10][20] - Non-GAAP EBITDA for Q1 2025 was $24 million, an increase of $13 million year-over-year but a decrease of $23 million from the previous quarter [10][21] Business Line Data and Key Metrics Changes - The XT Amplify program contributed to revenue growth, alongside SaaS and XPath services, including specialty pharmacy services [17][18] - The company continues to see strong customer interest in its long-term innovation roadmap [8][17] Market Data and Key Metrics Changes - The demand environment tracked well with expectations, showing market share gains and continued interest in the product platform [7][8] - Leading health systems in various states have invested in Omnicell solutions to improve efficiency and patient safety [12][14] Company Strategy and Development Direction - The company aims to capture greater market share across inpatient and outpatient settings, grow predictable recurring revenue, and expand its cloud-based platform, Omnisphere [7][8] - The focus remains on redefining medication and supply management across healthcare [6][7] - The company is adapting its supply chain to mitigate tariff impacts, including dual sourcing and near-shoring efforts [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the current tariff environment and emphasized the importance of supply chain optimization [11][15] - The company remains optimistic about long-term growth strategies aligning with the vision of the Autonomous Pharmacy [15][28] - Management noted that the first quarter typically has the lowest revenue and profitability, with expectations for growth throughout the year [20][21] Other Important Information - The anticipated impact from tariffs for 2025 is approximately $40 million to non-GAAP EBITDA, leading to adjustments in guidance [11][26] - Cash and cash equivalents at the end of Q1 2025 were $387 million, up from $369 million at the end of Q4 2024 [21] Q&A Session Summary Question: Can you describe the outlook for tariff distribution between Omnicell and customers? - Management indicated that currently, they are not passing significant price increases to customers but may adjust discounts in the future [32] Question: What is the cadence of the $40 million tariff impact? - The total impact is expected to be $40 million, with about $5 million in Q2 and the remainder in the second half of the year [39][41] Question: Are there any fundamentals driving reacceleration in demand for pharmacy IT? - Management noted that specialty pharmacy is a top topic among providers, leading to more strategic discussions about investments [48][50] Question: What are the assumptions behind the new EBITDA guidance range? - The guidance changes were primarily driven by tariff impacts, with mitigation actions including relocating supply chains and evaluating pricing [54][59] Question: How long will it take to disintermediate supply chain exposure to China? - Management stated that while some components will still flow through China, they are taking actions to move sourcing to other regions over time [66] Question: How does the hospital buying environment look currently? - Management reported no slowdown in revenue or installation processes, indicating a positive environment despite potential macroeconomic challenges [86]